High-dose anthracyclines in the treatment of advanced primitive neuroectodermal tumors in adults--a single institution experience.
Primitive neuroectodermal tumors (PNET) are rare malignancies of presumed neural crest origin, most often presenting as bone or soft tissue masses in the trunk or axial skeleton, in children and young adults. Treatment of advanced PNET in adults is not clearly defined in the literature. Data concerning dose-intensive chemotherapy regimens for poor-risk patients with those tumors are sparse, due to rarity of PNET in adults, their diverse presentation, the variable treatment procedures applied and the absence of direct comparisons. On the other hand, the role of anthracyclines in the treatment of advanced soft tissue sarcomas is well known and substantial. Six advanced PNET patients were treated at the Institute for Oncology and Radiology of Serbia, during last five years, with high-doses of doxorubicin or epidoxorubicin combined with cisplatin. The paper reviews each of our patients, discussing how does chemotherapy influence the outcome in these patients, in context of the feasibility of high-doses of anthracyclines in advanced settings. High dose anthracyclines (epidoxorubicin 150 mg/m2) in combination with cisplatin 120 mg/m2 induced a complete response lasting for 63+ months in a patient with desmoplastic medulloblastoma of the cerebellum metastatic to bones and bone marrow. The same treatment but with the epidoxorubicin dose of 180 mg/m2 induced a complete response in a patient with olfactory neuroblastoma. Administration of high dose Doxorubicin (75 mg/m2) seems feasible in association with irradiation treatment in patients with extraosseal Ewing sarcoma/PNET but the place of high dose chemotherapy within this setting remains to be determined.
Radosavljević
D
D
Institute for Oncology and Radiology of Serbia, Belgrade, Yugoslavia.
Jelić
S
S
Tomasević
Z
Z
Matković
S
S
Stamatović
L
L
Nikolić-Tomasević
Z
Z
Popov
I
I
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002528:Cerebellar Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use*; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy; D009447:Neuroblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy; D018242:Neuroectodermal Tumors, Primitive / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin